Status:

COMPLETED

Dexmedetomidine as Adjunctive Therapy for Alcohol Withdrawal

Lead Sponsor:

University of Colorado, Denver

Collaborating Sponsors:

Hospira, now a wholly owned subsidiary of Pfizer

Conditions:

Acute Alcohol Withdrawal

Eligibility:

All Genders

18-85 years

Phase:

NA

Brief Summary

This study is designed to evaluate dexmedetomidine as adjunctive therapy of severe alcohol withdrawal of medical ICU patients. Specifically, this study will assess whether adjunctive dexmedetomidine r...

Detailed Description

The objectives of this randomized, double-blind, placebo controlled, dose escalation study are a) to determine if adding dexmedetomidine to symptom-triggered, standard therapy of severe alcohol withdr...

Eligibility Criteria

Inclusion

  • Severe alcohol withdrawal defined by a CIWA score ≥ 15 and the need for at least 16 mg of lorazepam over a four-hour period. All lorazepam doses, whether oral or intravenous, will contribute to the cumulative amount.
  • Patients receiving standard therapy for severe alcohol withdrawal according to a symptom-triggered alcohol withdrawal protocol. Lorazepam is the preferred benzodiazepine agent for patients requiring ICU admission due to alcohol withdrawal.
  • Informed consent within 36 hours of qualifying for the study.

Exclusion

  • Patients \< 18 years of age or \> 85 years of age.
  • Patients receiving benzodiazepine therapy for purposes other than alcohol withdrawal (e.g. sedation).
  • Patients with alcohol withdrawal not requiring ICU admission.
  • Patients receiving epidural administration of medication(s).
  • Comatose patients by metabolic or neurologic affectation.
  • Patients with active myocardial ischemia or second- or third-degree heart block.
  • Moribund state with planned withdrawal of life support.
  • Patients with known or suspected severe adverse reactions to dexmedetomidine (or clonidine).
  • Pregnant females or females suspected of being pregnant

Key Trial Info

Start Date :

September 1 2009

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

October 1 2012

Estimated Enrollment :

24 Patients enrolled

Trial Details

Trial ID

NCT00936377

Start Date

September 1 2009

End Date

October 1 2012

Last Update

May 12 2016

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

University of Colorado Hospital

Aurora, Colorado, United States, 80045